532 / 1851
GOG 0265
•
Phase II study
–
Persistent or recurrent cervical Ca
–
One prior line of systemic therapy
–
3 doses of ADXS
•
12-month OS = 38.5% in 26 patients
|
|
532 / 1851
GOG 0265
•
Phase II study
–
Persistent or recurrent cervical Ca
–
One prior line of systemic therapy
–
3 doses of ADXS
•
12-month OS = 38.5% in 26 patients